📈Technical Analysis
The stock has shown a powerful uptrend over the past 5–6 years, with a sharp rally from ₹1,000 to ₹3,500. For the past year, the ₹3,500–₹3,600 zone stood strong as resistance. With the release of the positive Q1 FY26 results, Torrent has decisively broken above this supply zone accompanied by higher volumes—something not seen earlier this year.
After the breakout, prices rose to ₹3,800 and then retested the broken zone, which now appears to be offering support. Provided this zone continues to hold and is followed by bullish candlestick confirmation, the stock looks set for further upside.
Targets:
🎯 ₹3,800 (Target 1)
🎯 ₹3,900 (Target 2)
🎯 ₹4,000 (Target 3)
Stop Loss: Below the support zone at ₹3,400. If prices fall below this, bullish outlook is invalidated.
💰Q1 FY26 Financial Highlights (vs Q4 FY25 & Q1 FY25)
The stock has shown a powerful uptrend over the past 5–6 years, with a sharp rally from ₹1,000 to ₹3,500. For the past year, the ₹3,500–₹3,600 zone stood strong as resistance. With the release of the positive Q1 FY26 results, Torrent has decisively broken above this supply zone accompanied by higher volumes—something not seen earlier this year.
After the breakout, prices rose to ₹3,800 and then retested the broken zone, which now appears to be offering support. Provided this zone continues to hold and is followed by bullish candlestick confirmation, the stock looks set for further upside.
Targets:
🎯 ₹3,800 (Target 1)
🎯 ₹3,900 (Target 2)
🎯 ₹4,000 (Target 3)
Stop Loss: Below the support zone at ₹3,400. If prices fall below this, bullish outlook is invalidated.
💰Q1 FY26 Financial Highlights (vs Q4 FY25 & Q1 FY25)
- Total Income: ₹3,178 Cr (↑ +7.4% QoQ vs ₹2,959 Cr; ↑ +11.2% YoY vs ₹2,859 Cr)
- Total Expenses: ₹2,146 Cr (↑ +7.6% QoQ vs ₹1,995 Cr; ↑ +9.8% YoY vs ₹1,955 Cr)
- Operating Profit: ₹1,032 Cr (↑ +7.0% QoQ vs ₹964 Cr; ↑ +14.2% YoY vs ₹904 Cr)
- Profit Before Tax: ₹738 Cr (↑ +11.0% QoQ vs ₹665 Cr; ↑ +12.5% YoY vs ₹656 Cr)
- Profit After Tax: ₹548 Cr (↑ +10.0% QoQ vs ₹498 Cr; ↑ +19.9% YoY vs ₹457 Cr)
- Diluted EPS: ₹16.19 (↑ +10.1% QoQ vs ₹14.71; ↑ +19.9% YoY vs ₹13.50)
This performance reflects robust execution across both domestic and international markets.
🧠Fundamentals & Strategic Highlights
Domestic Market Strength: India revenues grew ~11%, driven by outperforming chronic therapies (13% growth vs 9% IPM growth)
Global Growth:
US business expanded by ~19%
Brazil saw 11% growth
Analyst Sentiment: Citi raised its target price to ₹4,380, citing sustained margin expansion and branded portfolio gains
M&A Plans: Torrent is acquiring a majority stake in JB Chemicals for ₹18,000–₹19,500 Cr, positioning the company among India’s top five pharma giants
✅Conclusion
Torrent Pharma’s technical breakout, backed by a wholesome Q1 performance and strategic M&A moves, positions it favorably for renewed upside. A failure to hold above ₹3,500 would challenge this view.
Disclaimer:lnkd.in/gJJDnvn2
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.